+1 (704) 266-3234

Global Tuberculosis Drug Market 2017-2021

Published on: Feb 2017 | From USD $3500 | Published By: INFINITI RESEARCH | Number Of Pages: 76

About Tuberculosis Drug
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and often affects the lungs. It spreads from person to person through the air in the form of a cough, sneeze or spit. TB affects adults more when compared with children.

Technavio’s analysts forecast the global tuberculosis drug market to grow at a CAGR of 3.17% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global tuberculosis drug market for 2017-2021. To calculate the market size, the report considers the volume and services.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Tuberculosis Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Lupin
• Otsuka Novel Products
• Pfizer
• Sandoz
• Sanofi
Other prominent vendors
• AstraZeneca
• Archivel Farma
• bioMérieux
• Cepheid
• EIKEN CHEMICAL
• Epistem
Market driver
• Increase in outbreak of TB-HIV co-infections
• For a full, detailed list, view our report

Market challenge
• Insufficient demand and high drug cost in developed countries
• For a full, detailed list, view our report

Market trend
• Focus on development of shorter TB drug regimens
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.




Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

PART 03: Research Methodology

PART 04: Introduction


Key market highlights


PART 05: Key pipeline

PART 06: Market landscape


Market overview
Market size and forecast
Five forces analysis


PART 07: High burden countries (HBCs)


Categorization of HBCs


PART 08: TB diagnostics


Overview


PART 09: Market segmentation by disease type


Global latent TB market
Global active TB market


PART 10: Market segmentation by drug class


Global first-line anti-TB drugs market
Global second-line anti-TB drugs market


PART 11: Geographical segmentation


TB drugs market in Americas
TB drugs market in EMEA
TB drug market in APAC


PART 12: Market drivers


Increase in outbreak of TB-HIV co-infections
Emergence of MDR-TB and XDR-TB strains
Increasing incidence of TB in Africa and Asia


PART 13: Impact of drivers

PART 14: Market challenges


Insufficient demand and high drug cost in developed countries
Liberal regulations and lack of awareness in developing countries
Limited diagnostic procedures


PART 15: Impact of drivers and challenges

PART 16: Market trends


Increased spending on TB diagnostic kits
Focus on development of shorter TB drug regimens
Increased focus on TB vaccine development


PART 17: Vendor landscape


Competitive scenario
Key news


PART 18: Key vendor analysis


Lupin
Otsuka Novel Products
Pfizer
Sandoz
Sanofi
Other prominent vendors


PART 19: Appendix


List of abbreviations


PART 20: Explore Technavio
List of Exhibits

Exhibit 01: Pipeline analysis

Exhibit 02: Key clinical trials

Exhibit 03: Global TB drugs market snapshot

Exhibit 04: Global TB drugs market 2016-2021 ($ millions)

Exhibit 05: Opportunity analysis in global TB drugs market

Exhibit 06: Five forces analysis

Exhibit 07: List of major HBCs

Exhibit 08: Advanced technologies used for TB diagnostics

Exhibit 09: Tests recommended for diagnosis of active TB

Exhibit 10: Drugs used as first-line anti-TB agents

Exhibit 11: Global first-line anti-TB drugs market 2016-2021 ($ millions)

Exhibit 12: Drugs used as second-line anti-TB agents

Exhibit 13: Global second-line anti-TB drugs market 2016-2021 ($ millions)

Exhibit 14: TB drugs market scenario in Americas

Exhibit 15: TB drugs market in Americas 2016-2021 ($ millions)

Exhibit 16: Number of TB cases reported in US 2010-2015

Exhibit 17: TB drugs market scenario in EMEA

Exhibit 18: TB drugs market in EMEA 2016-2021 ($ millions)

Exhibit 19: TB drugs market scenario in APAC

Exhibit 20: TB drugs market in APAC 2016-2021 ($ millions)

Exhibit 21: Impact of drivers

Exhibit 22: Impact of drivers and challenges

Exhibit 23: Testing process in BCG vaccines

Exhibit 24: Competitive structure analysis of global TB drug market 2016

Exhibit 25: Lupin: Key highlights

Exhibit 26: Lupin: Strength assessment

Exhibit 27: Lupin: Strategy assessment

Exhibit 28: Lupin: Opportunity assessment

Exhibit 29: Otsuka Novel Products: Key highlights

Exhibit 30: Otsuka Novel Products: Strength assessment

Exhibit 31: Otsuka Novel Products: Strategy assessment

Exhibit 32: Pfizer: Key highlights

Exhibit 33: Pfizer: Strength assessment

Exhibit 34: Pfizer: Strategy assessment

Exhibit 35: Pfizer: Opportunity assessment

Exhibit 36: Sandoz: Key highlights

Exhibit 37: Sandoz: Strength assessment

Exhibit 38: Sandoz: Strategy assessment

Exhibit 39: Sandoz: Opportunity assessment

Exhibit 40: Sanofi: Key highlights

Exhibit 41: Sanofi: Strength assessment

Exhibit 42: Sanofi: Strategy assessment

Exhibit 43: Sanofi: Opportunity assessment

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3500
USD $4500
USD $5000
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.